OneSpaWorld Holdings (OSW) has announced its upcoming quarterly dividend, maintaining a consistent per-share payout of $0.040 since its previous dividend on Mar 26, 2025. This aligns with the average dividend of the past ten distributions, reflecting stability in the company's dividend policy. Shareholders of record as of the ex-dividend date, May 21, 2025, will receive their cash dividend on Jun 4, 2025. The company's dividend type is described as a cash dividend, underscoring their commitment to returning value to investors.
Recently,
has been in the news, attracting attention from institutional investors and market analysts alike. As of late, Cubist Systematic Strategies LLC significantly reduced its holdings in
by 82.8% during the fourth quarter. Conversely,
Corp increased its stake, highlighting contrasting investor sentiments. In the broader market, OneSpaWorld's stock opened at $19.31, displaying robust financial ratios with a debt-to-equity ratio of 0.18 and a quick ratio of 1.29. Over the past week, analysts have reiterated a "buy" rating for OSW, despite recent adjustments to price objectives by brokers such as TD Securities and Stifel Nicolaus.
In related developments, Leonard I Fluxman, CEO and Executive Chairman of
, reportedly sold 76,577 common shares in recent transactions. This insider activity has piqued interest, potentially influencing investor perceptions of the company's future trajectory. Additionally, new strategic positions have been acquired by various hedge funds, including Smartleaf Asset Management LLC, which significantly boosted its holdings, reinforcing confidence in the company's long-term prospects.
In conclusion, OneSpaWorld Holdings remains a focal point for investors, with recent activities highlighting shifts in institutional ownership and insider transactions. The upcoming ex-dividend date on May 21, 2025, is crucial for investors aiming to benefit from this dividend payout, as any stock acquisitions post this date will not qualify for the current dividend distribution.
Comments
No comments yet